Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Interim Results from Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma

Published: Tuesday, December 10, 2013
Last Updated: Tuesday, December 10, 2013
Bookmark and Share
Adaptimmune announces that study continues to report encouraging response rates, safety and proof of mechanism.

Interim results from a Phase I/II clinical trial using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells have been released. The study Chair presented these updated results today at the annual meeting of the American Society of Hematology (ASH). 

The clinical trial was designed as a single arm open label study where patients are given standard of care (autologous stem cell transplant). This is followed by infusion of a patient’s own T cells that have been genetically engineered to carry receptors that help the T cells recognize and attack tumors, while sparing healthy tissue. 

The objectives for the study are to evaluate the safety, bioactivity and anti-tumor effect of infusion of patients’ own T cells that have been genetically modified to express a high affinity T cell receptor (TCR) specific for a type of tumor antigen (protein) known as a cancer testis antigen (CT antigen). The target CT antigens in the study are NY-ESO-1 and LAGE-1. Anti-tumor responses are reported as best response by day 100 following the transplant and T cell infusion. 

The initial six patient phase was completed in 2012 and based on encouraging preliminary results announced at ASH last December, the study was extended to a target enrollment of 26 patients. To date, 21 patients have been enrolled. 20 patients have received engineered T cells and have been assessed at day 100 for tumor responses to the treatment. 19 patients have reached a minimum of six month follow-up and 15 patients have reached one year follow-up. 

After one year, patients are followed for disease status quarterly, and progression free and overall survival will be collected as the study follow-up matures. Patients are also monitored no less than bi-annually for safety and correlatives specific to the engineered T cells. 

Multiple myeloma is a hematologic cancer localized to the bone marrow and is currently incurable in most patients. With standard therapy, long-term response rates are low and the median survival for patients with this disease is three to five years. 

The clinical study focuses on this unmet medical need and includes patients who have received prior treatment for their myeloma or who have disease considered to be high risk, who are eligible for an autologous stem cell transplant (auto-SCT), and whose tumor expresses NY-ESO and/or LAGE-1. Auto-SCT is the transplant of a patient’s own stem cells, which is a standard of care for treatment of multiple myeloma in the U.S. Infusion of the gene modified T cells occurs two days following auto SCT. 2 

Dr. Aaron Rapoport, the Chair of the clinical study, presented abstract 766 entitled “Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR in Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated with Encouraging Post Auto-SCT Responses”. 

He reports that infusions of engineered T cells have been well tolerated. The overall best response rate at 100 days is 77%. This rate is encouraging in these patients, of whom approximately 50% have high risk disease, 25% have received prior transplant, and NY-ESO expression is associated with poor prognosis. 

Of the 20 patients treated to date, 13 have ongoing responses, and seven have progressed. In cases of disease progression, a concomitant loss or reduction of engineered T cells, or a loss of antigen positivity on recurring tumor has been observed. Consequently, the protocol has been modified to allow for additional infusions without concomitant transplant, provided the patient’s tumor continues to express target antigen. 

“The clinical responses seen in our patients are encouraging and are generally better than I expected from transplant alone,” says Dr. Rapoport, the Gary Jobson Professor in Medical Oncology at the University of Maryland School of Medicine and Associate Director of the Blood and Marrow Transplant Program at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. “I look forward to making this technology available to patients outside of the transplant setting.” 

Enrollment is nearly completed and a final study analysis in planned to start in late 2014. Interim safety and response data presented at the ASH conference is under preparation for publication in the first half of next year. 

“This study has provided us with important insights into the activity of NY-ESO T cells,” said Mr. James Noble, Chief Executive Officer of Adaptimmune. “It has been a privilege to work with this translational team and we are encouraged by progress to date on this study and our studies in solid tumor indications.” 

Additional study details and contact information for patients interested in finding out more about participation can be found at clincialtrials.gov, under trial identifier number NCT01352286. 

The study was originally developed by Dr. Carl H. June at the University of Pennsylvania (UPenn) Abramson Cancer Center and Dr. Rapoport. Dr. Rapoport is the lead clinical investigator at the University of Maryland and protocol Chair. Dr. Edward Stadtmauer is the lead clinical investigator at the UPenn Abramson Cancer Center, and Dr. Dan Vogl is a sub-investigator at UPenn. Dr. Michael Kalos led correlative studies at UPenn during his tenure as Director of the Translational and Correlative Sciences Laboratory (TCSL) at UPenn (now at Eli Lilly), and Dr. Simon Lacy is completing these studies at the TCSL on his behalf. Initially, Dr. June served as the regulatory sponsor (FDA representative) for the study and T cell manufacturing was performed at the Clinical Cell and Vaccine Production Facility at the University of Pennsylvania directed by Dr. Bruce Levine. In April 2013, following the Novartis engagement of UPenn for CD19 engineered T cell therapy in CLL and ALL, Adaptimmune assumed the sponsorship and T cell manufacturing roles for this study. Adaptimmune is also the financial sponsor for the study and owns the T cell receptor technology. 3 

Adaptimmune has also opened a new 10 patient pilot study, designed to evaluate the safety and anti-tumor effects of the engineered T cells without transplant. This trial is now enrolling at the University of Maryland in Baltimore, Maryland, and the City of Hope in Duarte, California. 

Additional study details and contact information for patients interested in finding out more about participation can be found at clincialtrials.gov, under trial identifier number NCT01892293. 

Other trials in ovarian cancer, melanoma and synovial sarcoma are ongoing in the U.S. and can be found on clincialtrials.gov


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Tuesday, July 21, 2015
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Tuesday, July 21, 2015
Adaptimmune Appoints Lawrence M. Alleva to its Board of Directors
Lawrence M. Alleva will join the Board as an independent, non-executive director.
Wednesday, March 11, 2015
Adaptimmune Strengthens Management Team with Key Executive Hires
Adaptimmune has strengthened its senior management team with the appointment of Dr. Rafael Amado, as Chief Medical Officer, and Adrian (Ad) Rawcliffe, as Chief Financial Officer.
Wednesday, March 04, 2015
Adaptimmune Announces Interim Results from Pilot Trial of NY-ESO T Cells
Study reports encouraging response rate and safety profile.
Friday, October 17, 2014
Adaptimmune Secures $104 Million in Series A Financing
Company will use funding to advance programmes in multiple cancer indications.
Friday, September 26, 2014
Adaptimmune Named as One of “Fierce 15” Biotech Companies of 2014
Company has created T-cell receptors which are deployed to target NY-ESO-1.
Tuesday, September 23, 2014
Adaptimmune Announces Full-time Appointment of James Noble as CEO
Appointment will become effective from 31st March.
Thursday, March 27, 2014
Adaptimmune Awarded £2.1m from the Biomedical Catalyst Fund
The prestigious award supports Adaptimmune’s clinical pipeline expansion.
Tuesday, March 25, 2014
Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells
Study continues to report encouraging response rates, safety and proof of mechanism.
Thursday, December 12, 2013
Adaptimmune Appoints Chairman of the Board
Dr Jonathan Knowles has been appointed as the new executive Chairman of the Board of Directors with immediate effect.
Thursday, November 21, 2013
Adaptimmune Announces Opening of Phase I/IIa Clinical Trial
Adaptimmune announced that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer.
Thursday, July 25, 2013
NeoStem’s Subsidiary, PCT Enters into Services Agreement with Adaptimmune
PCT to provide cell product development and manufacturing for Adaptimmune’s clinical trials.
Thursday, January 24, 2013
NeoStem Subsidiary Enters Into a Cell Therapy Manufacturing Services Agreement with Adaptimmune
PCT to provide cell product development and manufacturing for Adaptimmune’s clinical trials.
Monday, January 21, 2013
Adaptimmune Announces Exclusive License with Life Technologies
The exclusive license secures a critical component for commercial development of modified T cells.
Monday, January 07, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Researchers Find U.S. Breast Milk is Glyphosate Free
Washington State University scientists have found that glyphosate, the main ingredient in the herbicide Roundup, does not accumulate in mother’s breast milk.
Peering into the Vapors
Research suggests that e-cigarettes are much less harmful than previous studies have indicated.
New Technique for Mining Health-conferring Soy Compounds
A new procedure devised by U.S. Department of Agriculture (USDA) scientists to extract lunasin from soybean seeds could expedite further studies of this peptide for its cancer-fighting potential and other health benefits.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
Rice Disease-Resistance Discovery Closes the Loop for Scientific Integrity
Researchers reveal how disease resistant rice detects and responds to bacterial infections.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!